Articles tagged with Melanoma
Experts suggest that targeted screening programs for middle-aged and older patients using newer diagnostic tools could significantly reduce melanoma mortality rates. Studies in Australia and Germany have shown a substantial decrease in melanoma-related deaths after implementing comprehensive skin cancer screening programs.
Epidemiological and pre-clinical studies suggest coffee has a protective effect against non-melanoma skin cancers, but the link to cutaneous melanoma is less clear. A study found that high coffee intake was inversely associated with a 20% lower risk of malignant melanoma, especially in caffeinated coffee drinkers.
A University of Colorado Cancer Center study found that TAK-733, a next-gen melanoma drug, exhibited anti-cancer activity in 10 out of 11 patient tumor samples grown in mice. The drug showed significant shrinkage in tumors up to 100%, regardless of BRAF mutation status.
The Myriad myPath Melanoma test has been shown to improve patient care through more definitive diagnoses of skin lesions, particularly in difficult-to-call cases. This resulted in a 49% change in physicians' treatment recommendations for patients with melanoma subtypes.
A phase 2 clinical trial found that adding sargramostim to ipilimumab improved overall survival in patients with metastatic melanoma. The combination treatment also had lower toxicity compared to ipilimumab alone.
A phase 2 clinical trial found that combining ipilimumab with sargramostim improved overall survival by nearly five months and reduced serious side effects. The treatment combination also showed a higher one-year survival rate of 68.9% compared to 52.9% in the ipilimumab-only group.
Researchers found melanoma cells create their own 'green light' signal using lysophosphatidic acid (LPA) to spread quickly and aggressively. This 'breadcrumb trail' allows cancer cells to travel rapidly around the body, making treatment challenging.
Researchers analyzed cultural and historical forces to estimate historic changes in UV exposure contributing to the rise in melanoma cases. Changes in fashion and clothing design, as well as increased leisure time and sun exposure, are identified as key factors.
A phase 3 trial found that combining dabrafenib with trametinib significantly reduces disease progression and death risk in metastatic melanoma patients. The therapy results in a 67% complete or partial response rate compared to 51% on monotherapy.
Preliminary data from a phase III trial suggest nivolumab achieves better response rates and longer response durations than standard chemotherapy in patients with unresectable metastatic melanoma. The drug has a lower toxicity profile compared to chemotherapy, promoting a sustained immune response.
Combination therapy with vemurafenib and cobimetinib achieves greater progression-free survival and response rates than vemurafenib alone in BRAF-mutation positive melanoma. The study also shows a reduced incidence of skin-related side-effects with combination therapy.
The European Organisation for Research and Treatment of Cancer (EORTC) will showcase its latest cancer research findings at the ESMO 2014 Congress. The conference will feature various sessions, including a joint symposium on clinical trials and posters focused on immunotherapy and gastrointestinal tumors.
A recent study published in the Journal of the National Cancer Institute has established a link between longer telomeres and increased melanoma risk. The research team identified seven genetic variations associated with telomere length and found that those with the longest telomeres are at a 30% increased risk of developing melanoma.
A new study from the University of Leeds has uncovered a genetic risk factor for melanoma, with longer telomeres associated with a higher risk. The research found that individuals with shorter telomeres are at a 30% increased risk of developing melanoma.
The Wistar Institute and Penn Medicine have collaborated on a $12.1 million SPORE grant to develop new therapies for melanoma. The goal of this project is to translate fundamental laboratory discoveries into new therapeutics that will benefit patients with melanoma and other skin cancers.
A retrospective study found that 62% of veterans reported getting sunburned while deployed, and 29% noticed changes in their moles, highlighting a potential deficiency in sun protection among military personnel. The study suggests room for improvement in skin cancer prevention and early detection in the military population.
The myPath Melanoma test differentiates malignant melanoma from benign skin lesions with over 90% accuracy, reducing indeterminate diagnoses by 76%. This improved diagnostic tool also changed treatment recommendations in 35% of cases, supporting its integration into clinical practice.
A systematic review and meta-analysis of 19 studies found that airline pilots and cabin crews have a higher incidence of melanoma, with a combined standardized incidence ratio of 2.21 for any flight-based occupation. This increased risk is attributed to exposure to UV radiation during flights.
A study found that high-mitotic rate melanomas are more likely to occur on the head and neck, grow rapidly, and be present in older men with a history of solar keratosis. These tumors have distinct clinical features, including nodular structure and amelanosis, which may pose a challenge to timely detection.
Acral melanomas, which affect the hands and feet, have unique DNA damage patterns not caused by UV radiation. Researchers sequenced tumor samples and found distinct genetic faults driving this rare skin cancer. Understanding these faults may lead to better treatments for acral melanoma.
Researchers have developed a new hand-held device that uses photoacoustic microscopy to accurately measure the depth of melanoma tumors in living tissue. This technology has the potential to improve diagnosis, prognosis, and treatment planning for melanoma patients by providing valuable information on tumor volume.
A new UK study reveals that a genetic defect in the melanocortin1 receptor (MC1R) may make people more susceptible to developing melanoma. The study found that MC1R defects contribute to melanoma development by delaying DNA repair and increasing cancerous mutations.
Research conducted at Texas Biomedical Research Institute found that sunscreen use in infancy and childhood reduces malignant melanoma incidence in adulthood by 10-fold. The study used a natural animal model, gray short-tailed opossums, to test the effectiveness of sunscreen against UV-induced melanoma.
A study found that selumetinib improved cancer progression-free survival time and tumor response rate in patients with advanced uveal melanoma, but had no impact on overall survival. Treatment-related adverse events were common, affecting nearly all patients.
A comprehensive clinical trial found that SPECT/CT imaging detected significantly more sentinel lymph node involvement with various types of cancers, including melanoma, breast carcinoma, and pelvic malignancies. This improved imaging technique has the potential to alter surgical planning and improve patient outcomes.
The Myriad myPath Melanoma test accurately differentiates malignant melanoma from benign skin lesions with a sensitivity of 90% and specificity of 91%. This improves the standard of care for patients with melanoma, enabling healthcare providers to deliver more objective and confident diagnoses.
A study by Mayo Clinic researchers found that the size of tumors before treatment is a strong predictor of response to immunotherapy drug MK-3475. The findings suggest that decreasing baseline tumor size through surgery or other means may be more effective in inducing long-lasting remissions.
Researchers have made significant strides in developing innovative immunotherapies that activate the body's immune response to fight cancer. The new treatments show high activity against advanced melanoma and demonstrate substantial decrease in melanoma recurrence risk.
A rare type of melanoma that affects darker skins is almost twice as likely to recur as other similar types of skin cancer. The study found that acral lentiginous melanoma has a high recurrence rate, especially in small tumors.
A study published in JNCI: Journal of the National Cancer Institute found that indoor tanning increases melanoma risk, regardless of burn history. Researchers matched 1167 melanoma patients with 1101 control subjects and found nearly four times more indoor tanners among those with zero burns.
Researchers at Cancer Research UK Manchester Institute have found that blocking the MLK family of four enzymes can prevent rapid resistance to vemurafenib, a treatment for advanced melanoma. This breakthrough could lead to new targeted therapies for metastatic melanomas with limited treatment options.
A sunburn risk monitor, Smartsun, is now available for purchase online. The device, worn as a waterproof wristband, changes color in response to UV radiation levels, warning users of potential skin damage.
Researchers found that patients who visited a specialist prior to melanoma diagnosis had a significantly lower risk of dying from the disease. This suggests that being invested and an advocate for one's own health may play a crucial role in improving prognosis.
The technology is being showcased at the AACR Annual Meeting, where researchers are highlighting its potential for cancer research. Studies have demonstrated the use of ddPCR to track treatment response in melanoma patients and quantify mutant genes in plasma and serum.
A nationwide study in Sweden found that single men are more likely to die of cutaneous malignant melanoma. The researchers discovered that this applies to men of all ages, regardless of education level or residence. Early detection is crucial for survival, as skin cancer can be cured if treated early enough.
Researchers have discovered that specific genetic mutations can increase the risk of melanoma by deactivating a gene that protects chromosomes from damage. This finding has significant implications for early detection and treatment strategies.
Sentinel node biopsy has significantly improved 10-year disease-free survival rates and melanoma-free survival for melanoma patients, reducing the need for extensive lymph node surgery. The procedure has become a worldwide standard in diagnosing melanoma, thanks to Moffitt Cancer Center's pioneering role in its development and teaching.
A decade-long study confirmed the effectiveness of lymphatic mapping and sentinel-node biopsy in detecting melanoma's early spread to lymph nodes, significantly prolonging patients' survival rates. The technique spares patients from unnecessary surgery and substantial costs for those with non-spreading tumors.
Two TAU researchers received $1.35 million in funding for their proposals on melanoma cell movement to the brain and tumor disarmament. Prof. Satchi-Fainaro's team aims to develop targeted nanotherapies, while Dr. Markel's team seeks to enhance immunotherapy success rates.
A Mayo Clinic study found a significant rise in skin cancer among middle-aged adults, with incidence increasing nearly eightfold between 1970 and 2009. Women between 40 and 50 showed the highest rates of increase, while men were more likely to have deeper lesions.
Researchers developed a radiopharmaceutical for identifying melanoma metastases, with higher sensitivity than FDG PET/CT. The treatment, using the same molecule as both a diagnostic and therapeutic agent, showed promising survival rates for patients.
Researchers developed a new statistical model, NOIA, which showed increased power for detecting genetic effects and interactions in cutaneous melanoma. The study identified significant associated genes HERC2, MC1R, and CDKN2A, providing new insights into the influence of gene-gene interactions on melanoma risk.
A new study published by SU2C researcher Roger S. Lo suggests that combinatory therapy may be effective in suppressing drug resistance in the treatment of melanoma. The research found that targeting both the MAPK and PI3K-PTEN-AKT pathways can suppress early and late resistance to BRAF inhibitors.
Researchers at Huntsman Cancer Institute will study the role of the c-KIT gene in melanoma, a devastating skin cancer that often develops resistance to treatment. The new funding will support studies using a novel melanoma mouse model to test whether active c-KIT can initiate melanoma.
A study of 4846 patients treated with ipilimumab reveals that some can survive for up to 10 years, with a plateau in overall survival starting around three years. This finding provides valuable insight into the long-term efficacy of the treatment and its potential as a benchmark for future medicines.
Researchers discovered a potential target for melanoma therapy in the S6K protein and found that a triple combination of drug inhibitors halted the growth of resistant tumors. Early studies also showed no evident signs of toxicity, making this approach a promising new strategy to combat drug-resistant melanoma.
The EORTC trial found that vaccination with GM2/KLH-QS-21 did not improve relapse-free or overall survival rates for patients with stage II melanoma. The vaccine was expected to stimulate antibodies against the GM2 ganglioside, but instead, it led to a higher risk of death and decreased survival rates.
A study found that sleep apnea severity can independently predict melanoma aggressiveness, with more severe cases showing faster tumor growth and deeper invasion. Researchers hope this link may lead to new therapeutic possibilities for people with both conditions.
Recent advances in melanoma research have put the deadly skin cancer at the forefront of cancer research, raising hopes that scientists and clinicians may have cornered the deadliest form of skin cancer. New diagnostic tools and targeted therapies are showing promise in blocking cancer-causing signaling pathways.
A study published in the Journal of the American College of Surgeons found that melanoma recurrence 10 or more years after initial treatment occurs in over 6% of patients. Patients who experience late recurrences tend to live longer and have better survival rates compared to those whose cancer recurs within the first three years.
Researchers found that the experimental drug selumetinib significantly improved progression-free survival, with nearly 16 weeks of PFS, and showed significant tumor shrinkage in patients with advanced uveal melanoma. This breakthrough offers a new treatment option for a historically untreatable disease.
A new study of over 1 million Israeli adolescents found a quadrupled higher risk of skin cancer among those of European origin and those immigrating from Europe. Childhood sun exposure is identified as a clear preventable risk factor for melanoma in Israel's subtropical climate.
Researchers at Mayo Clinic discovered that patients with inflammatory bowel disease (IBD) are at a 37% increased risk of developing melanoma. IBD causes chronic inflammation in the intestines, which may contribute to this elevated cancer risk.
The US Centers for Disease Control and Prevention (CDC) presents promising strategies to curb the use of indoor tanning devices. These methods aim to tackle not only the risk factors linked with indoor tanning but also the broader social determinants that may drive such behavior.
A study published in PLOS Medicine found that white people with a history of non-melanoma skin cancer, such as basal cell and squamous cell carcinoma, are at increased risk of developing other forms of cancer in the future. The analysis revealed a 15% to 26% higher risk for men and women, respectively.
Researchers found that combining CT imaging findings with baseline serum lactate dehydrogenase levels can accurately predict patient survival. Patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT scans are likely to have a favorable response to therapy.
Researchers found that HIF1 and HIF2 are overexpressed in melanoma tumors, promoting the spread of cancer through the lymphatic system. Suppressing these transcription factors reduced the rate of metastasis in mouse models.
Researchers have decoded the platyfish genome, revealing insights into cancer development and complex behaviors. The study found altered genes involved in live-bearing birth and unique molecular changes, shedding light on the evolution of these traits.
The Melanoma Research Alliance has awarded $9.6 million to 49 scientists at 26 institutions globally, focusing on accelerating treatment approaches for metastatic melanoma and understanding its initiation. The grants bring the total MRA funding to almost $48 million.
Gossypin, a naturally-occurring substance, has been shown to inhibit the growth of human melanoma cells and reduce tumor volume in mice. The compound may have great therapeutic potential as a dual inhibitor of mutations that occur in the vast majority of melanoma patients.